Spyre Therapeutics (SYRE) Net Income towards Common Stockholders (2015 - 2026)

Spyre Therapeutics has reported Net Income towards Common Stockholders for 12 years, with the latest figure at -$69.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 54.12% year-over-year to -$69.0 million; the trailing twelve-month figure through Mar 2026 stood at -$179.4 million (up 14.12% YoY), and the FY2025 full-year result was -$155.2 million, up 25.39% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$69.0 million, down from -$62.5 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$11.2 million in Q3 2025, with the low at -$217.1 million in Q2 2023.
• Historically, Net Income towards Common Stockholders has averaged -$50.3 million across 5 years, with a median of -$40.1 million in 2023.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 872.45% — and 2025, when it surged 83.8%.
• Spyre Therapeutics' Net Income towards Common Stockholders stood at -$18.8 million in 2022, then slumped by 235.67% to -$63.2 million in 2023, then advanced by 10.9% to -$56.3 million in 2024, then decreased by 11.07% to -$62.5 million in 2025, then dropped by 10.36% to -$69.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$69.0 million (Q1 2026), -$62.5 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.